0001140361-26-004924
SEC filingGrace Therapeutics, Inc. reported a net loss of $2.3 million for Q3 2026 (period ending December 31, 2025), driven by a loss from operating activities of $2.4 million. Operating expenses totaled $2.5 million, consisting of $2.0 million in general and administrative expenses and $462,000 in research and development expenses (net of government assistance). The company generated $134,000 in total other income, primarily from interest and other income ($170,000) and a change in fair value of derivative warrant liabilities ($40,000), partially offset by foreign exchange loss ($4,000). Cash flow from operations was negative $7.2 million, but financing activities provided $3.7 million from common warrant exercises, resulting in a net decrease in cash of $3.5 million. The balance sheet shows $68.5 million in total assets, including $19.2 million in current assets (with $18.7 million in cash and cash equivalents) and $41.1 million in intangible assets. Total liabilities are $3.6 million, with stockholders' equity at $64.9 million. The company's cash position decreased from $22.1 million to $18.7 million during the quarter.
Grace Therapeutics, Inc. reported a net loss of $2.3 million for the third quarter of fiscal year 2026 (period ending December 31, 2025). The loss from operating activities was $2.4 million, driven by $2.0 million in general and administrative expenses and $462,000 in research and development expenses (net of government assistance). Total other income of $134,000 partially offset the operating loss, consisting primarily of $170,000 in interest and other income and $40,000 from the change in fair value of derivative warrant liabilities. Basic and diluted loss per share were both reported as $0. The company's weighted average shares outstanding were 16.9 million for both basic and diluted calculations.
No revenue figures are disclosed in the provided financial data. The income statement shows only expense items and losses, with no revenue line items present. The company appears to be in a pre-revenue stage, focusing on research and development activities. The $462,000 in research and development expenses (net of government assistance) represents the company's investment in its therapeutic pipeline. Without revenue disclosure, growth drivers and segment breakdown cannot be analyzed from the available data.
The company reported negative operating income of $2.4 million, resulting from $2.5 million in total operating expenses. No gross margin or operating margin percentages can be calculated due to the absence of revenue figures. The cost structure is dominated by general and administrative expenses ($2.0 million), which represents 80% of total operating expenses. Research and development expenses ($462,000) account for the remaining 20% of operating costs. The net loss margin cannot be calculated without revenue figures. Stock-based compensation of $616,000 represents a significant non-cash expense affecting profitability.
Cash flow from operating activities was negative $7.2 million, significantly higher than the net loss of $2.3 million due to changes in working capital, including a $106,000 decrease in receivables and a $320,000 decrease in trade payables. Investing activities showed no cash flow. Financing activities provided $3.7 million from common warrant exercises, net of $327,000 in stock issuance costs. The net decrease in cash was $3.5 million, bringing cash and cash equivalents to $18.7 million. The balance sheet shows total assets of $68.5 million, including $41.1 million in intangible assets and $8.1 million in goodwill. Total liabilities are $3.6 million, consisting of $1.3 million in current liabilities and $2.3 million in deferred tax liability. Stockholders' equity stands at $64.9 million, with an accumulated deficit of $227.3 million.
No forward-looking guidance, strategic priorities, or specific risk factors are disclosed in the provided financial data. The filing contains only financial statements without management discussion and analysis (MD&A) sections that typically include outlook information. The company's cash position of $18.7 million, combined with the $7.2 million quarterly cash burn from operations, suggests the need for additional financing unless operational efficiency improves. The $4.0 million raised from warrant exercises during the quarter demonstrates continued access to capital markets. No information is provided about pipeline progress, regulatory milestones, or strategic initiatives that would inform the company's future prospects.